coronavirus diseases

[키워드] 95% CI 95% confidence interval acute respiratory syndrome adjust adverse event adverse events age all-cause mortality analysed Analysis applicability approach arising Arm Asymptomatic asymptomatic infection baseline benefit caution CENTRAL certainty certainty of evidence change citation Cochrane COVID-19 Study Register Combination comparison Comparisons composite endpoint control group coronavirus disease coronavirus diseases Corticosteroid Corticosteroids COVID-19 Data collection death Descriptive statistics Dexamethasone Diagnosis direction disease disease severity dosage dosages dose doses doses of corticosteroids effective Effects eligible endpoints estimate Ethnicity evaluated Evidence excluded Factor FIVE Follow-up Gender heterogeneous high risk hospital-acquired infections hospitalised hyper-inflammation identify include index individual Inhaled inhaled corticosteroids inherent invasive Invasive mechanical ventilation invasive ventilation life limitation long-COVID majority median medRxiv methodology Methylprednisolone Middle East Middle East respiratory syndrome Mild Mild disease Mortality MOST New nine non-hospitalised occurred Other outcomes outcome outcomes Outpatient outpatients participant Participants Patient people with COVID-19 Placebo Population Quality Quality of life randomisation randomised randomised controlled trial Randomised controlled trials RCT RCTs reduce reduction in regimen reported Respiratory Support risk risk difference risk of bia risk ratio Safe Science Citation Index searched Selection Serious Adverse Events Severe acute respiratory syndrome standard care subgroup subgroups subsequent suspected diagnosis symptomatic symptomatic COVID-19 syndrome systematic review systemic systemic corticosteroid systemic corticosteroids the WHO therapy topical treat Treatment Trial Ventilation ventilator-free day Ventilator-free days Web of Science WHO ICTRP
[DOI] 10.1002/14651858.CD014963 PMC 바로가기 [Article Type] Review